[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100442374":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":19,"locations":25,"responsibleParty":42,"collaborators":18,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":18,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":18,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":18,"overallStatus":28,"whyStopped":18,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"The First Hospital of Jilin University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"R-CDOP","EXPERIMENTAL","Rituximab 375mg\u002Fm2, D0; Cyclophosphamide 750mg\u002F m2, D1; Doxorubicin hydrochloride liposome 30-35mg\u002F m2, D1; Vindesine 3mg\u002F m2, D1; Prednisone 60mg\u002F m2, D1\\~5.",[13],"Combination Product: R-CDOP",[15],{"type":16,"name":9,"description":11,"armGroupLabels":17,"otherNames":18},"COMBINATION_PRODUCT",[9],null,[20],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},"Ou BAI, doctor","CONTACT","13039046656","oubai16@163.com",[26],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"The First Bethune Hospital of Jilin University","RECRUITING","Changchun","Jilin","130021","China","CN",{"type":35,"coordinates":36},"Point",[37,38],125.32278,43.88,{"lat":38,"lon":37},[41],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"SPONSOR_INVESTIGATOR","oubai, MD\u002FPhD","Director","100442374","r-cdop-regimen-in-the-treatment-of-newly-diagnosed-non-hodgkins-lymphoma-with-high-tumor-burden-100442374",false,"NCT05040555","R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden","A Prospective Clinical Study of R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden","Inclusion Criteria:\n\n1. Histologically immunohistochemistry and imaging confirmed diffuse large B-cell lymphoma or follicular lymphoma grade 3B;\n2. Has at least one evaluable or measurable lesion according to Lugano response criteria;\n3. Patients with at least one of the following high tumor burden Involvement of at least 3 nodal sites (each with a diameter greater than 3 cm); nodal or extranodal mass \\> 7cm in its greater diameter; Hepatomegaly and splenomegaly (infiltration confirmed by PET-CT; Spleen: female \\> 15cm, male \\> 16cm); Pleural\u002Fperitoneal effusion; Lactate dehydrogenase (LDH) three times the upper limit of normal; PET-CT TMTV \\>220cm3;\n4. Patients previously untreated;\n5. Patients aged over 18 and under 75 years;\n6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0\\~2;\n7. International Prognostic Index (IPI) score \\> 1, or with extranodal mass diameter ≥7cm;\n8. Life expectancy ≥ 6 months;\n9. Left Ventricular Ejection Fraction (LVEF) ≥ 50%;\n10. Patients must sign informed consent and be willing and able to comply with the requirements of visits, treatment, laboratory tests and other research requirements stipulated in the research schedule.\n\nExclusion Criteria:\n\n1. Pregnant or lactation and patients of childbearing age who do not want to take contraceptive measures;\n2. Abnormal liver function \\[total bilirubin \\> 1.5 times of the upper limit of normal value; Alanine aminotransferase\u002FAspartate aminotransferase (ALT \u002F AST) \\> 2.5 times of upper limit of normal value for patients without liver metastasis ; ALT \u002F AST \\> 5 times of upper limit of normal value for patients with liver metastasis \\], abnormal renal function (serum creatinine \\> 1.5 times of upper limit of normal value) ;\n3. Absolute Neutrophil Count (ANC)\\\u003C1.5×10\\^9\u002FL or Platelet (PLT)\\\u003C 75 × 10\\^9\u002FL;\n4. Hypersensitivity to any study drug or its ingredients;\n5. Patients with significant and uncontrolled cardiovascular disease or history;\n6. Persons with mental disorders\u002Funable to obtain informed consent;\n7. Lymphoma infiltrates the central nervous system;\n8. Previous history of malignant tumor;\n9. HIV infection; HBV infection (HBV-DNA\\> 2000 IU\u002Fml);HCV infection (HCV-RNA\\>200 IU\u002Fml);\n10. The investigator determined not suitable to participate in this study.","ALL","18 Years","75 Years",{"count":57,"type":58},64,"ESTIMATED","INTERVENTIONAL",[61],"NA","A single-center, prospective clinical study to evaluate the efficacy and safety of R-CDOP (Rituximab, Cyclophosphamide, Doxorubicin hydrochloride liposome, Vindesine, Prednisone ) in the treatment of newly diagnosed high tumor burden non-Hodgkin's lymphoma, which has previously shown promising efficacy.",[64,65],"Diffuse Large B Cell Lymphoma","Follicular Lymphoma Grade 3B","2021-09-15",{"date":68,"type":69},"2021-09-16","ACTUAL",{"date":71,"type":69},"2021-08-30",{"date":73,"type":58},"2028-09-01",{"name":44,"class":6},1]